Dallas, TX, July 23, 2015 – Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that Covance Drug Development has relocated its clinical research unit (CRU) in Dallas, TX, to a new, fit-for-purpose clinical research facility. The new unit, which opened earlier this month, has expanded from 72 to 100 medical beds and is located in the same building as the prior unit. In addition, a LabCorp patient service center will be co-located in the CRU, at which patients will have an opportunity to learn more about volunteering and participating in early stage clinical trials.
“Our new Dallas facility combines advanced medical care with numerous volunteer-friendly amenities,” said Dr. Herman Scholtz, Vice President & General Manager, Early Clinical Services. “We have invested in a highly customized facility designed to facilitate the safety and quality of our studies and to enhance our clients’ and volunteers’ experience. In addition, we are excited about the unique opportunity to educate patients about our clinical trials and complement our local patient recruitment capabilities through the future LabCorp patient service center. This innovative combination of resources is another illustration of the strategic and operational synergies that LabCorp and Covance are gaining through our combination.”
With more than 55,000 square feet of space, the new CRU includes a cGMP pharmacy, dedicated ophthalmology procedure rooms, an advanced telemetry system, and a glucose clamp suite, as well as dedicated screening and outpatient visit areas. The pharmacy includes three sterile and two non-sterile manufacturing suites, which allows the site to meet current Good Manufacturing Practices. The telemetry system enables the team to perform continuous, high-quality data monitoring, supporting improved monitoring of study participants and quick adjustments to treatment regimens, when necessary.
The Dallas clinic employs approximately 75 medical and professional staff with plans to expand to 120 employees.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.